Home | Top News | World | US News | Politics | Economy | Sports | Technology | Science | Lifestyle | People | Recalls

Drug Maker Pays $360 Million to Settle Investigation Into Charity Kickbacks


Prosecutors accused Actelion Pharmaceuticals, which Johnson & Johnson acquired in 2017, of violating Medicare laws by funneling money through a patient-assistance charity. (Ny Times Science) More More

Similar stories

Big Pharma settlements in kick-back cases fuel doubts on patient groups, too - JD Supra

Big Pharma settlements in kick-back cases fuel doubts on patient groups, too  JD Supra

Patients now have more than half a billion reasons to wonder whether advocacy groups that purport to speak up for the special needs of folks with diseases and ...

Posted on 12 December 2018 | 1:40 pm | Google News

Reuters Health News Summary - Devdiscourse

Reuters Health News Summary  Devdiscourse

Following is a summary of current health news briefs.

Posted on 7 December 2018 | 9:26 pm | Google News

Drugmaker Actelion Agrees To Pay $360M To Settle Kickback Investigation - Kaiser Health News

Drugmaker Actelion Agrees To Pay $360M To Settle Kickback Investigation  Kaiser Health News

The Justice Department alleged that Actelion Pharmaceuticals violated federal law by using a foundation fund to funnel kickback payments aimed at inducing ...

Posted on 7 December 2018 | 9:39 am | Google News

Friday, December 7, 2018 - Kaiser Health News

Friday, December 7, 2018  Kaiser Health News

Patient advocates say the state's new staffing regulations are a good start toward better protecting the frail, but the nursing home industry contends they're too ...

Posted on 7 December 2018 | 9:33 am | Google News

First Edition: December 7, 2018 - Kaiser Health News

First Edition: December 7, 2018  Kaiser Health News

Today's early morning highlights from the major news organizations.

Posted on 7 December 2018 | 6:46 am | Google News

Recon: FDA Approves Roche Combo for First-Line Lung Cancer Use; NICE OKs Yescarta for Adults With Lymphoma - Regulatory Focus

Recon: FDA Approves Roche Combo for First-Line Lung Cancer Use; NICE OKs Yescarta for Adults With Lymphoma  Regulatory Focus

Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing. In Focus: US. Democrats are suddenly eyeing a valuable pharma ...

Posted on 7 December 2018 | 3:00 am | Google News

Copyright © 2018 LastMinuteStuff.com
Contact info